<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114710</url>
  </required_header>
  <id_info>
    <org_study_id>2009NLY078</org_study_id>
    <nct_id>NCT02114710</nct_id>
  </id_info>
  <brief_title>Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock</brief_title>
  <official_title>Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing PLA General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether stress doses of hydrocortisone attenuate
      coagulation dysfunction in patients with septic shock. And discuss the probable mechanism by
      which little doses of hydrocortisone influence coagulation system in sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were randomized to receive either low-dose hydrocortisone or matching
      placebo.Severity of coagulopathy was estimated using ISTH DIC score. We determined the
      complications and mortality in two groups, and analyzed the relationship between
      hydrocortisone and coagulopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>30 days after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical perioperative complications</measure>
    <time_frame>30 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical complications</measure>
    <time_frame>30 days after inclusion</time_frame>
    <description>MODS SOFA score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Coagulation Dysfunction in Septic Shock</condition>
  <condition>Hemodynamic Improvement Induced by Hydrocortisone</condition>
  <arm_group>
    <arm_group_label>Hydrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>little doses of hydrocortisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs</description>
    <arm_group_label>Hydrocortisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients(ageâ‰§18y)

          -  Admitted for septic shock were considered eligible if they had no life-threatening
             systemic disease (ASA groups 1~3)

        Exclusion Criteria:

          -  Lactation

          -  Mental disorders

          -  Disseminated cancer

          -  Secondary cancers

          -  Inflammatory bowel disease, or diseases hindering epidural analgesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Gao Tao</investigator_full_name>
    <investigator_title>Nanjing PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>coagulopathy</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>organ failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

